(NASDAQ: BCYC) Bicycle Therapeutics's forecast annual revenue growth rate of 29.23% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 49.33%, and while it is forecast to beat the US market's average forecast revenue growth rate of 11.84%.
Bicycle Therapeutics's revenue in 2025 is $36,898,000.On average, 6 Wall Street analysts forecast BCYC's revenue for 2025 to be $2,269,542,710, with the lowest BCYC revenue forecast at $738,792,425, and the highest BCYC revenue forecast at $4,142,761,260. On average, 5 Wall Street analysts forecast BCYC's revenue for 2026 to be $2,568,373,889, with the lowest BCYC revenue forecast at $738,792,425, and the highest BCYC revenue forecast at $4,971,313,512.
In 2027, BCYC is forecast to generate $6,179,066,511 in revenue, with the lowest revenue forecast at $2,250,209,824 and the highest revenue forecast at $11,462,329,946.